NU Skin Enterprises price to free cash flow NUS
Market value divided by free cash flow over the last twelve months, since 2011.
- Today, Oct 23, 2026
- 21.6×
- 10-year median
- 14.3×
- Against its 10-year history
- 82nd
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 2.9× to 494×
- Peer median
- 20.6×
NU Skin Enterprises' price to free cash flow is 21.6× as of Oct 23, 2026.
That is above its ten-year median of 14.3×, higher than on 82% of days in the last ten years.
Over that time it ranged from 2.9× in Oct 2024 to 494× in Oct 2023.
The median for 10 healthcare stocks of a similar size is 20.6×.
Price to free cash flow over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 21.6× | 5.9× | 23.2× |
| 2025 | 9.0× | 3.4× | 10.3× |
| 2024 | 3.7× | 2.9× | 24.3× |
| 2023 | 25.2× | 16.1× | 494× |
| 2022 | 16.2× | 11.8× | 44.1× |
| 2021 | 41.2× | 7.9× | 41.2× |
| 2020 | 10.2× | 9.6× | 17.3× |
| 2019 | 16.6× | 14.5× | 26.8× |
| 2018 | 16.9× | 15.0× | 22.4× |
| 2017 | 18.8× | 11.5× | 19.9× |
| 2016 | 11.9× | 5.9× | 15.3× |
| 2015 | 8.0× | 7.0× | 34.5× |
| 2014 | 22.7× | 11.2× | 36.3× |
| 2013 | 21.4× | 8.7× | 37.8× |
| 2012 | 8.0× | 7.9× | 27.4× |
| 2011 | 24.4× | 7.8× | 24.9× |
Against its peers
Companies in Healthcare nearest NU Skin Enterprises' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| NUSNU Skin Enterprises | 21.6× |
| UTMDUtah Medical Products | 20.6× |
| ELMDElectromed | 26.2× |
| NATRNatures Sunshine Products | 11.8× |
| PLXProtalix BioTherapeutics | 26.8× |
| PDEXPro DEX | 29.5× |
| INFUInfuSystem | 12.1× |
| VMDViemed Healthcare | 12.8× |
| EMBCEmbecta | 2.3× |
| ARVNArvinas | n/m |
| NRCNRC Health | 22.4× |
| Peer median | 20.6× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on NU Skin Enterprises
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.